Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of an Anti-SARS-CoV-2 Monoclonal Antibody and Response to Treatment in Individuals With Long COVID (outSMART-LC)

NCT05877508 is registered in ClinicalTrials.gov with Michael Peluso, MD as lead sponsor.

NCT NCT05877508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05877508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of an Anti-SARS-CoV-2 Monoclonal Antibody and Response to Treatment in Individuals With Long COVID (outSMART-LC)
Lead sponsor
Michael Peluso, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2023
Completion date
July 31, 2026
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long covid, post-acute covid-19, post-acute sequela of covid-19